CytomX Therapeutics, Inc. Interest Expense
CytomX Therapeutics, Inc. (CTMX) reported Interest Expense of $206.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2018-03-07
- CytomX Therapeutics, Inc. interest expense for the quarter ending 2017-03-31 was $206.00K, a 41.64% decline year-over-year.
- CytomX Therapeutics, Inc. interest expense for the quarter ending 2016-12-31 was $389.00K, a 3.46% increase year-over-year.
- CytomX Therapeutics, Inc. interest expense for the quarter ending 2016-09-30 was $482.00K, a 32.87% decline year-over-year.
- CytomX Therapeutics, Inc. interest expense for the quarter ending 2016-06-30 was $465.00K, a 13.97% increase year-over-year.
- CytomX Therapeutics, Inc. interest expense for fiscal 2016 was $1.69M, a 2.48% decline from fiscal 2015.
- CytomX Therapeutics, Inc. interest expense for fiscal 2015 was $1.73M, a 255.65% increase from fiscal 2014.
- CytomX Therapeutics, Inc. interest expense for fiscal 2014 was $487.00K, a 91.73% increase from fiscal 2013.
- CytomX Therapeutics, Inc. interest expense for fiscal 2013 was $254.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2017-03-31 | $206.00K 10-Q · filed 2017-05-05 | $595.00K derived: sum of 2 quarters · filed 2017-05-05 | $1.08M derived: sum of 3 quarters · filed 2017-05-05 | $1.54M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $871.00K derived: sum of 2 quarters · filed 2017-03-02 | $1.34M derived: sum of 3 quarters · filed 2017-03-02 | $1.69M 10-K · filed 2017-03-02 |
| 2016-09-30 | $482.00K 10-Q · filed 2016-11-03 | $947.00K derived: sum of 2 quarters · filed 2016-11-03 | $1.30M 10-Q · filed 2016-11-03 | $1.68M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $465.00K 10-Q · filed 2016-08-03 | $818.00K 10-Q · filed 2016-08-03 | $1.19M derived: sum of 3 quarters · filed 2018-03-07 | $1.91M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $353.00K 10-Q · filed 2017-05-05 | $729.00K derived: sum of 2 quarters · filed 2018-03-07 | $1.45M derived: sum of 3 quarters · filed 2018-03-07 | $1.85M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.09M derived: sum of 2 quarters · filed 2018-03-07 | $1.50M derived: sum of 3 quarters · filed 2018-03-07 | $1.73M 10-K · filed 2018-03-07 |
| 2015-09-30 | $718.00K 10-Q · filed 2016-11-03 | $1.13M derived: sum of 2 quarters · filed 2016-11-03 | $1.36M 10-Q · filed 2016-11-03 | $1.47M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $408.00K 10-Q · filed 2016-08-03 | $638.00K 10-Q · filed 2016-08-03 | $747.00K derived: sum of 3 quarters · filed 2017-03-02 | $864.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-03-31 | $230.00K 10-Q · filed 2016-05-06 | $339.00K derived: sum of 2 quarters · filed 2017-03-02 | $456.00K derived: sum of 3 quarters · filed 2017-03-02 | |
| 2014-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $226.00K derived: sum of 2 quarters · filed 2017-03-02 | $487.00K 10-K · filed 2017-03-02 | |
| 2014-09-30 | $117.00K 10-Q · filed 2015-11-23 | $378.00K 10-Q · filed 2015-11-23 | ||
| 2013-12-31 | $254.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |